MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
2.475
+0.015
+0.61%
Opening 13:37 12/06 EST
OPEN
2.450
PREV CLOSE
2.460
HIGH
2.520
LOW
2.330
VOLUME
1.16M
TURNOVER
0
52 WEEK HIGH
5.78
52 WEEK LOW
1.190
MARKET CAP
1.73B
P/E (TTM)
-1.5612
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SMMT last week (1127-1201)?
Weekly Report · 2d ago
ESGL, HNRA and SMX among pre-market losers
Esgl, hnra and smx among pre-market losers. Seelos therapeutics -43% on pricing of $5.55 million stock offering. Leslies -20% after q4 earnings release; farfetch ltd -16%; woof -14%.
Seeking Alpha · 11/29 13:23
Weekly Report: what happened at SMMT last week (1120-1124)?
Weekly Report · 11/27 09:41
Weekly Report: what happened at SMMT last week (1113-1117)?
Weekly Report · 11/20 09:41
Weekly Report: what happened at SMMT last week (1106-1110)?
Weekly Report · 11/13 09:39
Summit Therapeutics Inc: Current report
Press release · 11/07 15:03
Summit Therapeutics Inc: Quarterly report
Press release · 11/07 15:03
Summit Therapeutics GAAP EPS of -$0.09
Summit therapeutics reports q3 gaap eps of -$0.09. aggregate cash and cash equivalents totaled $200.5 million on september 30, 2023. summit therapeutic reported $654.7 million in cash and equivalents on december 31, 2022.
Seeking Alpha · 11/07 12:14
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company is engaged in research and development activities, primarily comprising oncology product research activities (including ivonescimab), and anti-infectives program activities. Ivonescimab, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. The Company’s preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (CRE) infections. It owns a genetics platform and a suite of software-based technologies (Discuva Platform).

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.